Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102381 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
A Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT07102381 is a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 125 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT07102381, a Phase 2 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Zanidatamab
Study Locations (20)
Texas
- Texas Oncology DFW - Dallas
- The University of Texas Southwestern Medical Center - Dallas
- Texas Oncology Gulf Coast - Houston
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Oncology Associates - Norfolk
- Shenandoah Oncology - Winchester
Nebraska
- Cancer Partners of Nebraska - Lincoln
- Nebraska Cancer Specialists - Omaha
New Jersey
- Astera Cancer Care (Formerly Regional Cancer Care Associates) - East Brunswick
- Medical Oncology Hematology Associates - Newark
California
- Oncology Institute - Long Beach
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- The Oncology Institute - Lakeland
Iowa
- Accellacare of McFarland - Ames
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2030-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07102381
The ClinicalTrials.gov registry entry for NCT07102381 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT07102381 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Virginia, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07102381 about?
NCT07102381 is a clinical study titled "A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer". The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
What is the current status of trial NCT07102381?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-09-24. Estimated completion is 2030-08-01.
What conditions does trial NCT07102381 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT07102381?
The interventions under investigation include: Trastuzumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Zanidatamab (DRUG).
Who is sponsoring clinical trial NCT07102381?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07102381 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.